Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | PRNP | P04156 | 6/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3238599 | 0.83 | ALDH1A1 (0.58) | RXFP1ALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL341524 | 0.82 | MEN1 (0.51) | RXFP1ALDH1A1HPGDHSD17B10KMT2A | |
| SCHEMBL3246512 | 0.81 | RXFP1 (0.56) | RXFP1ALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL9661173 | 0.80 | PKM (0.68) | RXFP1ALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL3248057 | 0.78 | ALDH1A1 (0.52) | RXFP1ALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL3245185 | 0.77 | KMT2A (0.57) | RXFP1ALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL10118118 | 0.76 | ALDH1A1 (0.53) | RXFP1ALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL4126057 | 0.76 | HSD17B10 (0.69) | RXFP1ALDH1A1HPGDHSD17B10ALOX15 | |
| SCHEMBL13044624 | 0.74 | SMN1; SMN2 (0.43) | ALDH1A1HPGDKMT2ANPSR1KDM4E | |
| SCHEMBL3759901 | 0.74 | LMNA (0.72) | RXFP1ALDH1A1HPGDHSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160256447-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES INC (US) | 2016-09-08 | — | — | US | disclosed |
| US-9181219-B2 | Compounds of modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140011840-A1 | Compounds of Modulating TRPV3 Function | HYDRA BIOSCIENCES, INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-8389546-B2 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120015979-A1 | Compounds for Modulating TRPV3 Function | Hydra Biosciences, Inc, (US) | 2012-01-19 | — | — | US | disclosed |
| US-7998980-B2 | Transient Receptor Potential channel modulators; N-(2-pyridinyloxy- or 2-pyridinylthio-alkanoyl)quinolines; acute or chronic pain, sensitivity, burns, diabetic neuropathy, psoriasis, eczema, dermatitis, post-herpetic neuralgia, migraine, incontinence, fever, hot flashes, osteoarthritis; depilatories | HYDRA BIOSCIENCES, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20080146611-A1 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES INC. (US) | 2008-06-19 | — | — | US | disclosed |
| WO-2008033564-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160256447-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | TRPV3, TRPV1, TRPV4 | RXFP1 378/4885ALDH1A1 3074/4885HPGD 797/4885 |
| US-20120015979-A1 | Compounds for Modulating TRPV3 Function | TRPV3, TRPV1, TRPV4 | RXFP1 378/4885ALDH1A1 3074/4885HPGD 797/4885 |
| US-20140011840-A1 | Compounds of Modulating TRPV3 Function | TRPV3, TRPV1, TRPV4 | RXFP1 401/4885ALDH1A1 3027/4885HPGD 798/4885 |
| US-20080146611-A1 | Compounds for modulating TRPV3 function | TRPV3, TRPV1, TRPV4 | RXFP1 378/4885ALDH1A1 3074/4885HPGD 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.